SCHEMBL160867

SCHEMBL160867

N=C(N)Nc1ccncc1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MDM2 Q00987 1/20 0.54
KDM4E B2RXH2 1/20 0.48
L3MBTL1 Q9Y468 1/20 0.48
TAAR1 Q96RJ0 2/20 0.47
CTSD P07339 1/20 0.46
KMT2A Q03164 3/20 0.44
MEN1 O00255 2/20 0.44
JAK2 O60674 1/20 0.44
TYK2 P29597 1/20 0.44
GAA P10253 1/20 0.43
PRKCI P41743 2/20 0.43
BCHE P06276 1/20 0.42
RAD52 P43351 1/20 0.41
NT5E P21589 1/20 0.41
EPHX1 P07099 1/20 0.41
POLB P06746 1/20 0.41
MAPT P10636 1/20 0.41
ROCK2 O75116 1/20 0.40
ROCK1 Q13464 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL11099750 0.98 MDM2 (0.52) MDM2KDM4EL3MBTL1TAAR1CTSD
SCHEMBL2949827 0.83 MDM2 (0.47) MDM2KDM4EL3MBTL1TAAR1CTSD
SCHEMBL27589604 0.82 TSHR (0.60) KMT2AMEN1POLBMAPT
SCHEMBL1996992 0.82 F2 (0.50) GAAMAPT
Hydrochloric Acid SCHEMBL6158030 0.81 TSHR (0.58) KMT2AMEN1POLBMAPT
SCHEMBL526209 0.76 ALDH1A1 (0.60) MDM2KDM4EL3MBTL1TAAR1CTSD
SCHEMBL1703485 0.76 MDM2 (0.54) MDM2KDM4EL3MBTL1TAAR1CTSD
SCHEMBL230957 0.76 MDM2 (0.67) MDM2KDM4EL3MBTL1TAAR1KMT2A
SCHEMBL5453827 0.76 BCHE (0.51) MDM2KDM4EL3MBTL1TAAR1BCHE
SCHEMBL399197 0.75 KIF11 (0.48) L3MBTL1TAAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1838696-B1 NOVEL CYANOGUANIDINE COMPOUNDS LEO PHARMA AS (DK) 2016-03-09 EP claimed
CN-103073486-A Polymorphs of N-(6-(4-chlorophenyloxy)hexyl)-N'-cyano-N\"-(4-pyridyl)guanidine, and preparation methods and applications thereof TIANJIN HEMEI BIOLOG TECHNOLOGY CO LTD 2013-05-01 CN claimed
EP-1838696-A1 NOVEL CYANOGUANIDINE COMPOUNDS Leo Pharma A/S (DK) 2007-10-03 EP claimed
WO-2006066584-A1 NOVEL CYANOGUANIDINE COMPOUNDS LEO PHARMA A/S (DK) 2006-06-29 WO claimed
EP-1397355-A1 PYRIDYL CYANOGUANIDINE COMPOUNDS Leo Pharma A/S (DK) 2004-03-17 EP claimed
CN-1121389-C Cyanoguanidine as cell proliferation inhibitor LEO PHARM PROD LTD (DK) 2003-09-17 CN claimed
WO-2002094813-A1 NOVEL PYRIDYL CYANOGUANIDINE COMPOUNDS LEO PHARMA A/S (DK) 2002-11-28 WO claimed
CN-1314890-A Cyanoguanidines as cell proliferation inhibitors LEO PHARM PROD LTD (DK) 2001-09-26 CN claimed
US-5292886-A Process for the preparation of 2-halomethyl-3,5-dimethyl-4-methoxypyridine halohydrate ESTEVE QUIMICA, S.A., A CORP. OF SPAIN (ES) 1994-03-08 US claimed
EP-0484265-A1 A process for the preparation of omeprazol CENTRO GENESIS PARA LA INVESTIGACION, S.L. (ES) 1992-05-06 EP claimed
US-12336981-B2 Compounds and compositions for the inhibition of NAMPT VALO HEALTH, INC. (US) 2025-06-24 US disclosed
US-12091385-B2 Pyridinylcyanoguanidine derivative and use thereof WANG, Zheming (CN) 2024-09-17 US disclosed
US-20240067607-A1 Pyridinylcyanoguanidine Derivative and Use Thereof WANG, ZHEMING (CN) 2024-02-29 US disclosed
CN-116283953-B Indoline compound containing thiazole structure, and preparation method and application thereof 沈阳药科大学 2024-02-02 CN disclosed
US-11873284-B2 Pyridinylcyanoguanidine derivative and use thereof WANG, Zheming (CN) 2024-01-16 US disclosed
CN-1258279-A Cyanoguanidines as cell proliferation inhibitors LEO PHARM PROD LTD (DK) 2000-06-28 CN disclosed
US-5292886-A Process for the preparation of 2-halomethyl-3,5-dimethyl-4-methoxypyridine halohydrate ESTEVE QUIMICA, S.A., A CORP. OF SPAIN (ES) 1994-03-08 US disclosed
EP-0484265-A1 A process for the preparation of omeprazol CENTRO GENESIS PARA LA INVESTIGACION, S.L. (ES) 1992-05-06 EP disclosed
EP-0061340-A1 New pharmaceutical compositions containing guanidinopyrimidines SMITHKLINE BECKMAN CORPORATION (US) 1982-09-29 EP disclosed
US-4336255-A DIURETICS SMITHKLINE CORPORATION (US) 1982-06-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240067607-A1 Pyridinylcyanoguanidine Derivative and Use Thereof NAMPT, NAPRT, NNMT MDM2 3869/4885KDM4E 1661/4885L3MBTL1 2804/4885
US-11873284-B2 Pyridinylcyanoguanidine derivative and use thereof NAMPT, NAPRT, NNT MDM2 3733/4885KDM4E 1773/4885L3MBTL1 2971/4885
US-12336981-B2 Compounds and compositions for the inhibition of NAMPT NAMPT, NNMT, NNT MDM2 4819/4885KDM4E 1401/4885L3MBTL1 3102/4885
US-12091385-B2 Pyridinylcyanoguanidine derivative and use thereof NAMPT, NAPRT, NNT MDM2 3733/4885KDM4E 1773/4885L3MBTL1 2971/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.